Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
TG Therapeutics, Inc. (NASDAQ:TGTX – Get Rating) – Equities research analysts at HC Wainwright upped their FY2022 earnings estimates for TG Therapeutics in a report released on Thursday, December 29th. HC Wainwright analyst E. White now expects that the biopharmaceutical company will post earnings per share of ($1.34) for the year, up from their previous estimate of ($1.36). HC Wainwright has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is ($1.32) per share. HC Wainwright also issued estimates for TG Therapeutics’ Q4 2022 earnings at ($0.28) EPS, Q1 2023 earnings at ($0.26) EPS, Q2 2023 earnings at ($0.22) EPS, Q3 2023 earnings at ($0.21) EPS, Q4 2023 earnings at ($0.20) EPS and FY2023 earnings at ($0.88) EPS.
TG Therapeutics (NASDAQ:TGTX – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.07. The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $3.37 million. TG Therapeutics had a negative net margin of 4,749.83% and a negative return on equity of 149.86%.
A number of other research firms also recently weighed in on TGTX. Evercore ISI raised their price target on shares of TG Therapeutics from $11.00 to $16.00 and gave the stock an “outperform” rating in a research report on Friday. B. Riley raised their price target on shares of TG Therapeutics from $17.00 to $23.00 and gave the stock a “buy” rating in a research report on Friday. StockNews.com assumed coverage on shares of TG Therapeutics in a research report on Wednesday, October 12th. They set a “sell” rating for the company. Bank of America raised their price target on shares of TG Therapeutics from $5.00 to $6.00 and gave the stock an “underperform” rating in a research report on Thursday. Finally, The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $4.00 to $6.00 and gave the stock a “sell” rating in a research report on Friday. Three research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $15.00.
TG Therapeutics Trading Up 13.8 %
TGTX opened at $11.83 on Monday. The firm has a market capitalization of $1.72 billion, a P/E ratio of -6.68 and a beta of 2.23. The firm’s 50 day moving average is $7.77 and its 200-day moving average is $6.70. TG Therapeutics has a 52-week low of $3.48 and a 52-week high of $20.69. The company has a quick ratio of 5.02, a current ratio of 5.02 and a debt-to-equity ratio of 0.70.
Hedge Funds Weigh In On TG Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of TGTX. Fifth Third Bancorp acquired a new position in shares of TG Therapeutics during the third quarter valued at $27,000. Allspring Global Investments Holdings LLC raised its stake in shares of TG Therapeutics by 517.1% during the third quarter. Allspring Global Investments Holdings LLC now owns 6,603 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 5,533 shares in the last quarter. Great West Life Assurance Co. Can bought a new stake in shares of TG Therapeutics during the third quarter valued at about $40,000. Macquarie Group Ltd. raised its stake in shares of TG Therapeutics by 102.3% during the second quarter. Macquarie Group Ltd. now owns 10,190 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 5,152 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY raised its stake in shares of TG Therapeutics by 28.7% during the third quarter. Metropolitan Life Insurance Co NY now owns 8,029 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 1,790 shares in the last quarter. Institutional investors and hedge funds own 68.06% of the company’s stock.
About TG Therapeutics
(Get Rating)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.
Further Reading
- Get a free copy of the StockNews.com research report on TG Therapeutics (TGTX)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It’s Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TG Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and TG Therapeutics wasn’t on the list.
While TG Therapeutics currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we’ll send you MarketBeat’s guide to pot stock investing and which pot companies show the most promise.
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
